Charles Schwab
OKUR

Charles Schwab’s OnKure Therapeutics OKUR Stock Holding History

Charles Schwab’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Buy
+63,640
New +$273K ﹤0.01% 3335
2024
Q2 		– Sell
-3,750
Closed -$62.3K – 3690
2024
Q1 		$62.3K Hold
3,750
– – ﹤0.01% 3347
2023
Q4 		$60K Hold
3,750
– – ﹤0.01% 3387
2023
Q3 		$286K Buy
3,750
+795
+27% +$54.1K ﹤0.01% 3227
2023
Q2 		$194K Buy
+2,955
New +$238K ﹤0.01% 3311
2022
Q2 		– Sell
-1,883
Closed -$56K – 3663
2022
Q1 		$56K Hold
1,883
– – ﹤0.01% 3513
2021
Q4 		$161K Buy
1,883
+546
+41% +$40.1K ﹤0.01% 3389
2021
Q3 		$100K Hold
1,337
– – ﹤0.01% 3382
2021
Q2 		$125K Buy
+1,337
New +$149K ﹤0.01% 3285

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab's OKUR Position: Q2 2026 in Review

Charles Schwab opened a new position in OnKure Therapeutics (OKUR) in Q2 2026: 63,640 shares worth $290K. The stake represents ﹤0.01% of the portfolio and ranks #3335 among its holdings. This is a return to the name: Charles Schwab previously reported a position in OKUR as recently as Q1 2024.

Charles Schwab first reported a position in OKUR in Q2 2021 and has held it in 9 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Charles Schwab held 63,640 shares of OnKure Therapeutics worth $290K as of Q2 2026.
  • OnKure Therapeutics was a new Charles Schwab position in Q2 2026.
  • OnKure Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3335 holding.
  • Charles Schwab first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.